Recent Highlights
- Picked up a load of good press for CEO Andrew Witty's developing ... Time for drug giants to jump into the patent pool? While drugmaking giant GlaxoSmithKline has picked up a load of good press for CEO Andrew Witty's developing world initiatives - from ploughing back some of the (tiny) profits made in ... The Guardian - business - 7 hours, 44 minutes ago
- Strengthened its ties with Anglo-German biotech company Cellzome by signing a second ... Glaxo signs Cellzome drug discovery deal GlaxoSmithKline has strengthened its ties with Anglo-German biotech company Cellzome by signing a second drug discovery deal worth up to 508 million euros (460 million pound). Reuters UK - business news - 20 hours, 31 minutes ago
- Been given a 76 per cent pay rise after one year in ... Glaxo boss gets £8m in rewards The chief executive of drugs developer GlaxoSmithKline has been given a 76 per cent pay rise after one year in the job. Andrew Witty took home more than £8m in ... City A.M. - 1 week, 5 days ago
- Fund and manage 1200 vehicles in its employee car ownership scheme on ... Zenith seals 1200-car employee ownership deal Zenith Provecta has won a contract with GlaxoSmithKline to fund and manage 1200 vehicles in its employee car ownership scheme on a sole supply and fully outsourced basis. BusinessCar - 1 week, 6 days ago
- “underrated and good value at prevailing levels.” The note praised the company’s ... Use pharma to ease the pain Drugs stocks can protect your portfolio from volatile price moves Kathleen Brooks THE last few weeks have been torrid for UK drugs giant GlaxoSmithKline. It has been accused of taking ... City A.M. - 2 weeks, 1 day ago
- To create 1,000 jobs in Britain in response to a plan to ... GlaxoSmithKline to create 1,000 jobs in UK GlaxoSmithKline is to create 1,000 jobs in Britain in response to a plan to cut tax to 10 per cent on revenues from patents developed in the UK. The Times - business - 2 weeks, 1 day ago
Latest Articles
2 days, 11 hours ago
AstraZeneca under pressure after drug disappointment
As the market edges higher, AstraZeneca is heading in the other direction following disappointing results for its cancer drug recentin. The experimental treatment failed in a late stage head to ...
The Guardian - business - 9:28 a.m. Monday 8th March 2010 GMT
View Article
Related Articles
Email to Friend
5 days, 3 hours ago
Xstrata gains ground as FTSE 100 jumps to 18 month high
Mining and financial shares led the way as the FTSE 100 surged to an 18 month high, helped by a return of investors' appetite for risk, hopes for a solution ...
The Guardian - business - 4:54 p.m. Friday 5th March 2010 GMT
View Article
Related Articles
Email to Friend
Glaxo could face $6bn Avandia liability, says UBS
GlaxoSmithKline could face a liability of up to $6bn following problems with its diabetes drug Avandia in the US, according to City followers of the company. Analysts at UBS said ...
The Guardian - business - 11:24 a.m. Friday 5th March 2010 GMT
View Article
Related Articles
Email to Friend
Abbott To Collaborate With GSK On Molecular Diagnostic Test To Select Candidate Patients For Future Skin Cancer Immunotherapy
Abbott (NYSE: ABT) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who ...
Medical News Today - 8 a.m. Friday 5th March 2010 GMT
View Article
Related Articles
Email to Friend
Commodity prices help push FTSE to a seven-week high
THE LONDON REPORT BRITAIN’S leading shares gained 0.9 per cent yesterday, boosted by strength in miners and oils, banks and life insurers, as upbeat US data lifted Wall Street. At ...
City A.M. - 12:46 a.m. Friday 5th March 2010 GMT
View Article
Related Articles
Email to Friend
6 days, 18 hours ago
FTSE rises as commodities and financials set the pace
THE LONDON REPORT BRITAIN’S leading shares gained 0.9 per cent yesterday, boosted by strength in miners and oils, banks and life insurers, as upbeat US data lifted Wall Street. At ...
City A.M. - 1:53 a.m. Thursday 4th March 2010 GMT
View Article
Related Articles
Email to Friend
6 days, 20 hours ago
Gentronix secures three-year Glaxo deal
Manchester-based university spin-out Gentronix has secured a three-year agreement with GlaxoSmithKline (GSK) to provide its GreenScreen HC and BlueScreen HC genotoxicity assays for use by GSK in genotoxicity screening.
Crain's Manchester Business - 11:54 p.m. Wednesday 3rd March 2010 GMT
View Article
Related Articles
Email to Friend
Vivus's Qnexa Will Become Decision Resources' Clinical Gold Standard In 2013 For The Treatment Of Obesity
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn ...
Medical News Today - 1 p.m. Wednesday 3rd March 2010 GMT
View Article
Related Articles
Email to Friend
1 week, 5 days ago
GlaxoSmithKline PLC : GSK files its Annual Report 2
6:20 PM: (GSK) GSK files its Annual Report 2
Investegate - 6:22 p.m. Friday 26th February 2010 GMT
View Article
Related Articles
Email to Friend
GlaxoSmithKline PLC : Total Voting Rights
12:24 PM: (GSK) Total Voting Rights
Investegate - 12:25 p.m. Friday 26th February 2010 GMT
View Article
Related Articles
Email to Friend
